In the randomised phase 3 TRIBE study, 1 first-line treatment of patients with metastatic colorectal cancer with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab ...

To our knowledge, this study is the first positive phase 3 trial in NASH and represents a landmark in the development of new therapies for an increasingly common chronic liver disease. 12–15 Treatment ...

Jenna Bush Hager is determined to keep her kids — Mila, 12, Poppy, 9, and Hal, 5 — reading this summer. Here's how she plans to do it. Jenna Bush Hager's 3-Step Plan to Get Her Kids to Read ...

Building on Ascletis’ positive Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned ...

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.

ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC). This ...

The survey received over 55,000 responses from train travellers located in over 396 districts of the country. 63 per cent of respondents were men, while 37 per cent of respondents were women. 41 per ...

Moonlake is running phase 3 studies of the nanobody in psoriatic arthritis and advancing the drug candidate toward pivotal trials in psoriasis, palmoplantar pustulosis and axial spondyloarthritis.

The samples were homogenized using Polytron Brinkmann Instruments, USA), as previously reported, and placed in a 96-well plate. 25 μL of 3, 3’, 5, 5’ - tetramethylbenzidine (Sigma, USA) and 100 μL of ...

WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company, today announced successful outcomes from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 ...